The #NCT03288493 phase I/II clinical trial aims at targeting the B-cell maturation antigen (BCMA) in patients with Relapsed/Refractory Multiple Myeloma using P-BCMA-101 autologous T stem cell memory (Tscm) Chimeric Antigen Receptor T cells (see Section 8). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.